Inflammaging Markers Still Matter—But They’re Part of a Network

Blood inflammation markers still carry the clearest signal

If you want one practical inflammaging readout, hs-CRP remains the sensible choice. Higher CRP or hs-CRP, along with higher IL-6, tracks with higher all-cause mortality in community-dwelling adults aged 40 and older. That conclusion comes from a 2025 systematic review and meta-analysis by Chen et al., the strongest direct human outcome evidence here.

The review also linked higher CRP or hs-CRP with higher odds of depression. It found less conclusive evidence for hospitalization, hospital readmission, anxiety, and TNF-alpha. That distinction matters. "Inflammaging" is a useful description of chronic low-grade inflammation with age; it is not a license to treat every cytokine on a lab report as an equally proven forecast of your future.

A separate 2023 Health and Retirement Study analysis reached a compatible conclusion in a U.S. population: a higher burden of inflammatory blood markers was associated with higher mortality. Two observational approaches pointing in the same direction make the association more credible. They do not establish that lowering a marker will, by itself, lower a person's risk of death.

That causal gap is not semantic nitpicking. CRP and IL-6 can rise because of existing illness, excess adiposity, smoking, renal dysfunction, poor diet, inactivity, medications, or physiological decline already under way. Inflammation may contribute to decline, reflect decline, or do both at once. Observational studies cannot completely separate those possibilities.

The newer idea is a network, not a replacement test

Researchers are increasingly asking whether inflammatory proteins capture only one visible part of a larger biological pattern. A 2025 Health ABC cohort study by Yao et al. examined metabolite patterns in older adults in relation to Healthy Aging Index status, later worsening of that index, and mortality. The authors interpreted the linked patterns through inflammation, oxidative stress, and mitochondrial dysfunction.

Metabolomics measures many small molecules involved in processes such as lipid and amino-acid metabolism. It can reveal that several pathways move together, which is useful when aging biology refuses to behave like a tidy flowchart. The Health ABC findings support the view that chronic inflammation sits within a wider metabolic and mitochondrial network associated with functional deterioration and mortality.

They do not show that a metabolomic score outperforms CRP or IL-6 in the clinic. The study was not a head-to-head superiority test against conventional inflammatory markers. More importantly, many metabolite associations weakened or lost statistical significance after the investigators adjusted for inflammatory biomarkers. That result suggests overlap between the metabolomic patterns and established inflammation measures. It supports interdependence, not a cleanly separate or clearly dominant metabolic signal.

This is a productive shift in interpretation. A high hs-CRP result may be less like a lone villain and more like one illuminated gauge on a crowded dashboard. But a crowded dashboard is not automatically a diagnostic system. Research-grade metabolomic profiles are not standardized clinical tools, and the Health ABC cohort does not establish individualized risk scoring for healthy middle-aged people who want to optimize aging.

How far does the biology reach?

Human cohort evidence establishes association. Animal work adds a reason the association might be biologically meaningful. In a 2023 inducible humanized IL-6 knock-in mouse study, six weeks of IL-6 induction increased pro-inflammatory and metabolic pathway activity, disrupted energy use, and produced lower grip strength, more treadmill falls, and a higher frailty index. The researchers also observed changes consistent with altered mitochondrial quality control in skeletal muscle.

That experiment makes it plausible that chronic IL-6 signaling can contribute to mitochondrial dysregulation and physical decline. Mice, however, are not small, whiskered confirmation of human causality. The model does not prove that the same IL-6-to-mitochondria pathway explains mortality associations in community-dwelling adults, nor does it tell us that suppressing IL-6 in otherwise healthy people will slow aging.

Can lifestyle change the signal?

Inflammation-related biology is modifiable. A 2025 systematic review and meta-analysis of lifelong exercise found evidence that exercise can affect low-grade inflammation associated with aging. A 2024 meta-analysis of randomized resistance-training trials in sarcopenic older adults also examined changes in body composition, muscle strength, and biomarkers.

Those findings support exercise as a reasonable upstream intervention for physical function and inflammatory biology. They do not prove a chain in which an exercise-driven drop in CRP or IL-6 causes lower mortality or prevents Healthy Aging Index decline. The exercise literature measures related but different endpoints: biomarkers, strength, body composition, and physical performance. Those are meaningful outcomes, but they are not interchangeable with hospitalization, frailty progression, or survival.

That limitation also appears in an exploratory 2025 physical-activity intervention study in older adults, which examined changes in physical performance and biomarkers. Such work can identify patterns worth testing, yet it cannot show that biomarker movement reliably translates into better long-term aging outcomes.

What to do with an elevated hs-CRP

Use hs-CRP as a risk signal that deserves context, not as a biological-age verdict. A transient infection, injury, hard training block, chronic disease, sleep disruption, smoking, and adiposity can all affect inflammatory measurements. A single elevated value is usually less informative than a repeat result interpreted alongside symptoms, medical history, medications, cardiometabolic risk, and other routine clinical data.

• Discuss persistently elevated hs-CRP with a clinician rather than treating it as a supplement-shopping prompt.
• Prioritize behaviors with established benefits for health and function, including regular physical activity and resistance training when appropriate.
• Treat IL-6 and TNF-alpha results cautiously. They are less standardized and less directly actionable in routine care than hs-CRP.
• View commercial metabolomics panels as exploratory unless they demonstrate validated prediction and useful clinical decisions in populations like yours.

The best current interpretation is modest but useful: higher inflammatory marker burden identifies higher risk, while metabolomics helps explain why that burden may travel with broader metabolic and mitochondrial disruption.

The verdict

Classic inflammatory markers have not been displaced. CRP or hs-CRP and IL-6 still have the clearest human prognostic links in this evidence base, especially for all-cause mortality. Metabolomic research makes the story more biologically coherent by connecting inflammation with oxidative stress and mitochondrial dysfunction, but it has not established an independent, superior, consumer-ready aging test.

Monitor established markers when clinically appropriate. Improve the upstream habits that support function and cardiometabolic health. Keep research metabolomics in the research category until human trials show that shifting these pathways improves outcomes people can actually feel or measure: less frailty, fewer hospitalizations, preserved function, or longer life.